AIM:LID

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

LiDCO Group Plc develops, manufactures, and sells hemodynamic monitoring equipment in the United Kingdom, the United States, Continental Europe, and internationally. More Details


Snowflake Analysis

Flawless balance sheet and fair value.


Similar Companies

Share Price & News

How has LiDCO Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: LID is more volatile than 90% of UK stocks over the past 3 months, typically moving +/- 22% a week.

Volatility Over Time: LID's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of UK stocks.


Market Performance


7 Day Return

0%

LID

-1.0%

GB Medical Equipment

1.2%

GB Market


1 Year Return

130.4%

LID

-7.4%

GB Medical Equipment

-9.6%

GB Market

Return vs Industry: LID exceeded the UK Medical Equipment industry which returned -7.4% over the past year.

Return vs Market: LID exceeded the UK Market which returned -9.6% over the past year.


Shareholder returns

LIDIndustryMarket
7 Day0%-1.0%1.2%
30 Day74.1%2.2%8.6%
90 Day34.3%-0.9%5.4%
1 Year130.4%130.4%-5.6%-7.4%-6.1%-9.6%
3 Year56.7%56.7%17.4%10.6%-0.6%-12.6%
5 Year34.3%34.3%38.3%27.1%23.3%-4.4%

Long-Term Price Volatility Vs. Market

How volatile is LiDCO Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is LiDCO Group undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: LID (£0.12) is trading below our estimate of fair value (£0.5)

Significantly Below Fair Value: LID is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: LID is good value based on its PE Ratio (24.8x) compared to the GB Medical Equipment industry average (43.3x).

PE vs Market: LID is poor value based on its PE Ratio (24.8x) compared to the UK market (20.4x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LID's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: LID is overvalued based on its PB Ratio (4.1x) compared to the GB Medical Equipment industry average (3.6x).


Next Steps

Future Growth

How is LiDCO Group forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

24.9%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as LiDCO Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has LiDCO Group performed over the past 5 years?

-17.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: LID has a large one-off gain of £200.0K impacting its July 31 2020 financial results.

Growing Profit Margin: LID became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: LID has become profitable over the past 5 years, growing earnings by -17.4% per year.

Accelerating Growth: LID has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: LID has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-36.8%).


Return on Equity

High ROE: LID's Return on Equity (16.5%) is considered low.


Next Steps

Financial Health

How is LiDCO Group's financial position?


Financial Position Analysis

Short Term Liabilities: LID's short term assets (£6.0M) exceed its short term liabilities (£2.4M).

Long Term Liabilities: LID's short term assets (£6.0M) exceed its long term liabilities (£822.0K).


Debt to Equity History and Analysis

Debt Level: LID is debt free.

Reducing Debt: LID has not had any debt for past 5 years.

Debt Coverage: LID has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: LID has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is LiDCO Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate LID's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LID's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LID's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LID's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LID's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.3yrs

Average management tenure


CEO

Matt Sassone

5.25yrs

Tenure

UK£317,000

Compensation

Mr. Matthew Sassone, also known as Matt, has been the Chief Executive Officer of LiDCO Group plc since August 14, 2015. Mr. Sassone served as Senior Vice President of Global Marketing at ArjoHuntleigh AB. ...


CEO Compensation Analysis

Compensation vs Market: Matt's total compensation ($USD421.28K) is about average for companies of similar size in the UK market ($USD343.91K).

Compensation vs Earnings: Matt's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Matthew Sassone
CEO & Director5.25yrsUK£317.00k0.10%
£ 29.4k
Tim Hall
CFO, Company Secretary & Director1.67yrsUK£241.23k0.041%
£ 11.7k
Terence O'Brien
Co-Founder & Member of Clinical Advisory Boardno datano data2.24%
£ 643.9k
David Band
Co-Founder29.83yrsno data2.93%
£ 841.4k
Shane Doorish
Head of North America3.83yrsno datano data

5.3yrs

Average Tenure

Experienced Management: LID's management team is seasoned and experienced (5.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Matthew Sassone
CEO & Director5.25yrsUK£317.00k0.10%
£ 29.4k
Tim Hall
CFO, Company Secretary & Director1.67yrsUK£241.23k0.041%
£ 11.7k
Terence O'Brien
Co-Founder & Member of Clinical Advisory Boardno datano data2.24%
£ 643.9k
Max Jonas
Member of Clinical Advisory Boardno datano datano data
Peter Grant
Independent Non-Executive Chairman3.5yrsUK£46.00k0.39%
£ 110.9k
Philip Cooper
Independent Non-Executive Director4.25yrsUK£30.00k1.09%
£ 313.3k
James Wetrich
Non-Executive Director1.25yrsUK£14.00k0.0081%
£ 2.3k

3.5yrs

Average Tenure

62yo

Average Age

Experienced Board: LID's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

LiDCO Group Plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: LiDCO Group Plc
  • Ticker: LID
  • Exchange: AIM
  • Founded: 1991
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: UK£28.691m
  • Shares outstanding: 244.17m
  • Website: https://www.lidco.com

Number of Employees


Location

  • LiDCO Group Plc
  • 16 Orsman Road
  • London
  • Greater London
  • N1 5QJ
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
LIDAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPJul 2001
LDGDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJul 2001
LDRU.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJul 2001

Biography

LiDCO Group Plc develops, manufactures, and sells hemodynamic monitoring equipment in the United Kingdom, the United States, Continental Europe, and internationally. The company provides LiDCOunity, a hemo...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/23 21:09
End of Day Share Price2020/11/23 00:00
Earnings2020/07/31
Annual Earnings2020/01/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.